Enimmune Corporation (TPEX:6564)
13.60
-1.10 (-7.48%)
Nov 20, 2026, 1:50 PM CST
Enimmune Revenue
Enimmune had revenue of 27.90M TWD in the half year ending June 30, 2026, with 37.26% growth. This brings the company's total for the last twelve months to 53.45M, up 26.56% year-over-year. In the year 2025, Enimmune had annual revenue of 48.19M with 20.74% growth. That makes Enimmune the 42,804th largest company in the world by revenue and 2,138th in Taiwan.
Revenue (ttm)
53.45M
Revenue Growth
+26.56%
P/S Ratio
18.35
Revenue / Employee
n/a
Employees
38
Market Cap
981.02M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.19M | 8.28M | 20.74% |
| Dec 31, 2024 | 39.92M | -3.58M | -8.23% |
| Dec 31, 2023 | 43.49M | -144.92M | -76.92% |
| Dec 31, 2022 | 188.42M | 78.59M | 71.56% |
| Dec 31, 2021 | 109.82M | 86.95M | 380.08% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 695.30M |
| Meribank Biotech | 408.48M |
| Abnova (Taiwan) | 337.63M |
| NeoCore Technology | 271.62M |
| TCI GENE | 251.39M |
| Lukas Biomedical | 170.01M |
| Holy Stone Healthcare | 47.51M |